Rolf Stahel
Rolf Stahel FRSA (born 21 April 1944)[1] is a Swiss businessman who was CEO of Shire Pharmaceuticals from March 1994 to March 2003, transforming it from a private $30 million company into a member of the FTSE 100.[2][3]
Rolf Stahel | |
|---|---|
| Born | April 21, 1944 Switzerland |
| Occupation | Businessman, CEO of Shire (1994-2003) |
He attended the six-week Advanced Management Program at Harvard Business School.[1]
He was non-executive chairman of EUSA Pharma from 2007 to 2012,[1] prior to its acquisition by Jazz Pharmaceuticals for $650 million.[4] He is currently Non-executive Chairman of Midatech Pharma PLC,[5] and founder Chairman of consultancy services firm Chesyl Pharma Ltd.[6]
He is a Fellow of the Royal Society of Arts and a member of the Royal Automobile Club.[1]
References
- "Stahel, Rolf, (born 21 April 1944), Chairman, Chesyl Pharma Ltd, since 2003; non-executive Chairman: Midatech Pharma plc, since 2014; Ampha Ltd, since 2016." WHO'S WHO & WHO WAS WHO. 28 Mar. 2018.
- "Shire chief's $10m 'golden hello' at AbbVie". Financial Times. Retrieved 28 March 2018.
- "Executive Profile: Rolf Stahel". Bloomberg L.P. Retrieved 28 March 2018.
- "Jazz Pharmaceuticals - Investor & Media - Press Release". jazzpharma.com.
- "Board of Directors". Midatech Pharma. Retrieved 28 March 2018.
- "Advisory Board". Imperial College Business School. Retrieved 30 March 2018.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.